We herein provide evidence that JAK2/STAT3 signaling might play a key role in the regulation of CLL-BMSC interactions and its inhibition enhances ibrutinib, counteracting the bone marrow niche. The gene discussed is STAT3; the disease is B-cell chronic lymphocytic leukemia.